Purpose: The 1.5 T Elekta MR-Linac, due to the construction of the system will have a maximum radiation field size in the superior-inferior patient direction of 22 cm at isocentre. The field size may impact on the patient groups which can be treated on the system. This technical note aims to address the question of which treatment sites will be affected by field size limitations on the MR-Linac. Methods: Using historical data for 11 595 cases over 2 yr treated at the authors' institution, the proportion of plans that would fit the MR-Linac's field size was determined for eleven patient groups. In addition, cervix plans were analyzed to determine the length of the two Clinical Target Volumes (CTVs) and any overlap between them. Results: With a 1 cm margin to allow for online plan adaption, 80% of all plans would be suitable for the MR-Linac due to the field size. This percentage increases to 100% for smaller tumor volumes such as prostate and brain. However, for cervix and three dose-level head and neck plans the percentage becomes 61% and 66%, respectively. Conclusion: The maximum radiation field size of the MR-Linac in the superior-inferior patient direction is 22 cm. With a 1 cm margin approximately 80% of all plans would be suitable for the MR-Linac with the available field size, decreasing to 61% for larger tumor volumes. For cervix patients this may motivate investigations into treating each CTV with a separate isocentre, allowing for careful control of matching fields.
INTRODUCTION
The MR-Linac 1 (Elekta, AB, Stockholm, Sweden) will provide excellent soft tissue contrast for on treatment imaging and will facilitate online plan adaption. These improvements are desirable for a number of treatment sites. 2 However, the maximum radiation field size in the superior-inferior patient direction will be 22 cm at isocentre which may limit the patients that can currently be treated on the system. Using data from a high patient throughput comprehensive cancer centre, this note aims to address the question of which treatment sites will be affected by field size limitations on the MR-Linac. Cervix patients will be investigated further to determine treatment methods enabling the use of the MR-Linac for this patient group.
MATERIALS AND METHODS

2.A. Patient selection
Planning data from 11 595 cases from a high patient throughput comprehensive cancer centre, treated between 2014 and 2016, were extracted from the clinical archive so that they could be analyzed. Patients were grouped by treatment site, defined by tumor site groups active within the MR-Linac international consortium. The treatment sites were prostate, cervix, rectum, lung, breast, Oesophagus, brain, and sarcomas, as well as head and neck plans with 1, 2, and 3 dose-levels. Breast plans here are only two-field breast and partial breast treatments, and do not include nodal regions. As Sarcomas are not labelled in a standard way in our planning system only anatomical sites have been extracted and labelled as extremities, these will be sarcomas but other sarcoma sites such as chest walls will have been excluded. All the cases were included in the analysis with sites being extracted using search terms on the name of the plans.
2.B. Analysis of results
The patient data were analyzed using an in-house python (PyCharm v4.5) script to separate the plans into conventional, step-and-shoot IMRT and VMAT plans, and then into treatment site. This was run on text files produced from in-house software to aid plan checking 3 for both Elekta and Varian Linacs.
2.B.1. Jaw position analysis
The maximum top and bottom jaw positions for each plan were extracted and combined to give an overall field size, correcting for collimator angle. The percentage of these that were greater than a given limit were then determined. The field size of the MR-Linac is 57.4 cm in the L-R lateral direction and 22 cm in the sup-inf direction. However, due to the requirement for daily plan adaption to correct for set-up errors and anatomical differences two further limits were analyzed in the sup-inf direction. A field size of 21 cm provides 5 mm superiorly and inferiorly for adaption and 20 cm provides 1 cm superiorly and inferiorly.
2.B.2. Cervix CTV analysis
MR image quality is superior in the pelvis and would be particularly useful for cervix patients where anatomical movement results in large target volumes. However, the number of cervix patients that can be treated with the MR-Linac is likely to be limited by the field size. In an extension of this analysis the methodology was applied to assess the extent and relative positions of the two CTVs. For cervix plans that included a CTV1 (which includes the primary disease, cervix, top 1/3rd of vagina and the parametrium 4 ) and a CTV2 (nodal regions) the length was extracted. In addition, the overlap (see sub-figures in Fig. 2 ) was extracted to assess the potential of using a dual isocenter technique to allow the treatment of the whole population of patients. Table I summarizes the results for the eleven patient groups. The number of patients analyzed is included and reflects the clinical workload of the department. The percentage of plans that will fit on the MR-Linac as a percentage of total cases for the disease site is included for the three field size limits. Data are illustrated in Fig. 1 
RESULTS
3.A. Jaw position analysis
3.B. Cervix CTV analysis
For cervix patients only 61.4% would fit using a 20 cm limit. However, for the 135 cervix patients with individual CTV1 and CTV2 volumes, the average length of CTV1was 6.0 cm with a standard deviation of 3.25 cm and CTV2 an average length of 11.2 cm with a standard deviation of 2.45 cm was found. This indicates that if treated as two separate target volumes, all patients would be treatable using the MR-Linac. The distance between the superior most point of CTV1 and inferior most point of CTV2 was determined and is shown in Fig. 2 . A negative value shows overlapping CTVs in the superior-inferior direction where as a positive value indicates underlapping. The majority of patients show an overlap in target volumes in the superior-inferior direction (76%). This indicates that for the majority of patients the treatment fields for each target would overlap. Therefore, careful creation and placement of junctions are required to ensure no over or under dosage of the target volumes.
DISCUSSION
The MR-Linac offers potential clinical benefits for improved image guidance and online plan adaption for a number of patient groups. 1, 5 However, a number of patient plans will not easily be treatable on the MR-Linac due to the maximum field size of 22 cm in the superior-inferior direction. This technical note has investigated the actual numbers of patients which can be treated for eleven treatment sites. To do this, we have utilized our large patient archive with over 11 500 plans analyzed. The large size of the data-set improves confidence in our results. The field size restriction is only one potential limiting factor in the percentage of patients that can be treated on the MR-Linac, for example due to the MR magnet, there are limitations on patients with implanted cardiac devices and patient tolerance (i.e. claustrophobia). It is worth noting that these results will be dependent on our institution's treatment protocols, including delivery technique, image guidance and PTV margin. However, we believe that the trends will remain valid across these treatment sites for other institutions.
We have investigated three limits, 22 cm (the physical maximum at isocentre), 21 cm and 20 cm. Due to the couch being unable to move within the MR-Linac bore each fraction will need online adaption. Small set-up errors, which can currently be corrected for with couch shifts, will be corrected by shifting the beams aperture, 6 although the couch does provide superior-inferior motion to load the patient into the machine. Due to the improved image quality, we will have the ability to adapt plans to the daily anatomy. 7 To allow for these workflows to be performed we may require an "adaption margin" in the superior and inferior direction. A field size of 21 cm allows for a 5 mm adaptive margin in the superior and inferior direction, however, this may be too conservative. Set-up errors of 3 mm are commonly seen on standard accelerators using lasers and cone beam CT. 8 The MR-Linac may not provide lasers as part of the current system so it is likely these set-up errors will prove to be larger. In addition, adapting for anatomical changes will depend on treatment site and can range from small (brain, 9 prostate) to large (cervix, lung 10 ). With these issues in mind it seems more sensible to use a 1 cm adaptive margin superiorly and inferiorly, therefore utilizing a 20 cm field length limit.
The superior imaging may allow a reduction in margins, additionally daily online adaption would minimize the set-up error component of PTV margins. This would facilitate a larger proportion of patients that could be treated. However, caution is needed when assuming superior image guidance can therefore lead to margin reduction. The introduction of new image guidance methods has led to patient detriment in the past, for example the use of fiducial markers in the prostate 11 and care needs to be taken to ensure we do not miss microscopic spread and occult disease.
The results are not unexpected, smaller tumor volumes will uniformly fit but for the larger volumes, cervix and 2/3 dose-level head and neck plans a significant proportion cannot be treated with a single field. MR guidance has particular merits in the pelvis were the soft tissue definition provides more information than cone beam CT. This technical note shows that to fully enable the MR-Linac across all sites other planning and treatment approaches are required. Such field sizes are routinely managed on commercial linear accelerators and these techniques need to be implemented for the MR-Linac, such as a dual isocentre technique.
The work studying the length of each CTV for cervix patients shows that each CTV on its own will be treatable on the MR-Linac which could motivate this method, although care would need to be taken to deal with the amount of overlap between the two CTVs and the creation and placement of the junction. This is especially pertinent when considering the potential anatomical changes and methods of online daily adaption. Furthermore, by splitting between primary and nodal target volumes, we may be better placed to deal with the differential motion between the two targets. These results motivate investigations employing a dual isocentre technique for treating the primary disease and elective nodal volumes separately, resulting in patients being treatable on the MRLinac. This will be the subject of a future study. Alternatively, by utilizing the slip ring gantry of the machine, perhaps a TomoTherapy style delivery may be a future possibility. 12 However, by utilizing a superior-inferior couch movement to correct for set-up errors in this direction we can significantly increase the number of eligible patients without resorting to more complex solutions. It is also worth noting that the MR imaging field is not limited in this manner and therefore remains a valuable clinical research tool for undertaking longitudinal imaging studies.
CONCLUSION
The percentage of all plans that could be treated on the MR-Linac considering the maximum superior-inferior field size, with a 1 cm margin, is approximately 80%. For smaller sites such as prostate and brain all patients will be suitable. However, for cervix and 3 dose-level head and neck plans this becomes 61% and 66%, respectively, that could be treated with current workflows. For longer treatment volumes, a different planning approach will be required. For Cervix patients, this may motivate investigations into whether it may be possible to treat each CTV with a dual isocentre technique, while taking care of any overlap, this will be the subject of a future planning study.
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